Concepedia

Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

Tom H. Johnston, Susan H. Fox, Matthew J. McIldowie, Matthew Piggott, Jonathan M. Brotchie

Journal of Pharmacology and Experimental Therapeutics · 2010 · 137 citations · 33 references

References

33

Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

Christopher G. Goetz, Barbara C. Tilley, Stephanie R. Shaftman et al. · Movement Disorders · 2008 · 7.5K citations · Full text

Medicine, Neurology, Functional Movement Assessment +16

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

Olivier Rascol, E. Melamed, Wolfgang H. Oertel et al. · The Lancet · 2005 · 634 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Institute of Laboratory Animal Resources.

Thomas L. Wolfle · 1995 · 618 citations

Humanities, Animal Sciences, Animal Welfare +12

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine: A Potent and Highly Selective Metabotropic Glutamate Subtype 5 Receptor Antagonist with Anxiolytic Activity

Nicholas D. P. Cosford, Lida Tehrani, Jeffrey Roppe et al. · Journal of Medicinal Chemistry · 2002 · 400 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys

Stella M. Papa, Thomas N. Chase · Annals of Neurology · 1996 · 290 citations

Medicine, Neurology, Pharmacology +17